drugset

drugset / Trial / NCT07504263

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

NCT07504263 ↗

Phase 1/2 Not yet recruiting 66 enrolled Recurv Pharma Inc

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1/2a Study of RP-001 in participants with Advanced Malignancies

Timeline

Start: 2026-04-23
Primary completion: 2027-12-01
Completion: 2028-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RP-001	Unknown	12 mg	—
Subject	RP-001	Unknown	25 mg	—
Subject	RP-001	Unknown	75 mg	—
Subject	RP-001	Unknown	150 mg	—
Subject	RP-001	Unknown	250 mg	—

Indications